Basic Neurosciences · Paper A
Inflammatory hypothesis of depression (IL-6 and CRP)
A subset of depression may not start in the synapse at all — it may start in the immune system, with mood as a late symptom of a body that thinks it is fighting an infection it does not have. Two markers carry almost all of the evidence here: interleukin-6 (IL-6), a signalling protein released by activated immune cells, and C-reactive protein (CRPC-reactive protein, a blood marker that rises with inflammation or infection.Read more →), a liver protein whose production IL-6 itself switches on. Both run modestly higher, on average, in people with major depressive disorder than in matched controls — but averages hide the real picture, because this pattern is concentrated in perhaps a third of depressed patients, not all of them, and an elevated CRP in any one patient in front of you is far more likely to mean an infection than a psychiatric diagnosis. You have to hold direction, strength and a guideline position in your head at once here, because the exam rewards precisely that kind of honesty and punishes overclaiming just as much as underclaiming.
The proposed chain runs from the periphery inward, and it is worth tracing cause to effect rather than memorising it as a list. Something outside the brain — a chronic low-grade inflammatory state, obesity, poor sleep, early-life adversity, or a genuine infection — activates peripheral immune cells, which release pro-inflammatory cytokines, IL-6 chief among them. IL-6 does two things worth separating clearly: it travels to the liver and switches on hepatic production of CRPC-reactive protein, a blood marker that rises with inflammation or infection.Read more →, which is why CRP is best understood as a downstream marker of IL-6 activity rather than an independent driver in its own right; and, separately, cytokines including IL-6 can signal into the brain, either through leaky regions where the blood-brain barrierA protective filter of tightly packed cells that limits which substances can pass from the blood into the brain.Read more → is naturally weaker, through active transport, or via vagus-nerve afferent signalling, and once there they activate the brain's own resident immune cells, microglia. Activated microglia release further cytokines locally and, importantly, upregulate an enzyme called indoleamine 2,3-dioxygenase (IDO), which diverts the amino acid tryptophan away from serotonin synthesis and down a different route called the kynurenine pathway instead — a pathway whose downstream product quinolinic acid is itself neurotoxic in excess. That diversion is why this model predicts fatigue, anhedoniaThe loss of the ability to feel pleasure from things that used to be enjoyable.Read more → and psychomotorRelating to the link between mental state and physical movement, such as being visibly slowed down or agitated.Read more → slowing specifically: it overlaps almost completely with the evolved "sickness behaviour" a body produces during any infection, which is a large part of why researchers were drawn to this hypothesis in the first place. None of this should be read as "inflammation causes depression" stated flatly — it is a plausible, partially supported mechanism operating in a subset of cases, sitting alongside, not replacing, other accounts of depression. The exam tends to test one link of this chain at a time, not the whole story at once.
When you catch a genuine infection, you already know the feeling before you know the diagnosis: exhausted, flat, unable to enjoy anything, wanting only to lie still. Researchers noticed decades ago that this "sickness behaviour" looks uncomfortably like a slice of depression, and started asking a genuinely testable question: could some depression be, at least partly, an immune response running with no actual infection to justify it? What follows is that idea from the ground up, together with the honest limits of how far the evidence actually goes.
The inflammatory hypothesis of depression proposes that immune signalling molecules called cytokines (proteins immune cells use to communicate with each other and with the rest of the body) can, in a subset of people, contribute to depressive symptoms by acting on the brain. The two markers with the most evidence behind them are interleukin-6 (IL-6), a cytokine released directly by activated immune cells, and C-reactive protein (), a protein your liver makes in large quantities whenever IL-6 tells it to. One picture holds all of this together, and it runs through the rest of the page. Think of chronic low-grade immune activation as a factory that has quietly switched on its emergency generator and left it running. IL-6 is the generator itself; CRP is the status light on the control panel outside, which tells you the generator is running but is not the generator.
"Inflammation and depression are linked" is true, and it is almost always over-read. Two readings in particular are unsafe: that every depressed patient has raised inflammatory markers, and that a raised in front of you explains a patient's low mood. The elevated pattern clusters in roughly a third of people with major depressive disorder, and CRP is such a non-specific marker — raised by infections, autoimmune disease, obesity, even recent injury — that finding it raised in a real patient should make you look for those causes first, not reach for a psychiatric explanation.
Start with what cytokines are actually for: coordinating your body's response to infection or injury, including behavioural changes like reduced appetite and reduced activity, which conserve energy for fighting illness. That is the generator switching on for a reason. IL-6, released by activated immune cells, can reach your brain — through weak points in the , active transport, or nerve signalling via the vagus nerve — and activate the brain's own resident immune cells, called microglia.
Activated microglia do two relevant things. They release further inflammatory signals locally, and they switch on an enzyme, indoleamine 2,3-dioxygenase, that diverts the amino acid tryptophan away from making serotonin and down a side route called the kynurenine pathway instead. That is the generator drawing off fuel the normal production line needed, and quinolinic acid — a kynurenine-pathway byproduct that is toxic to neurons in excess — is the exhaust settling on the factory floor.
Less tryptophan for serotonin, plus a neurotoxic byproduct accumulating, gives you a genuinely plausible route from immune activation to low mood, fatigue and slowed thinking, without needing to claim inflammation is the ONLY route to depression.
Work through this in three separate steps, because each one carries a different weight.
Step one, association. Meta-analyses pooling many studies (Dowlati and colleagues' early work, later confirmed by larger analyses) consistently find IL-6 and running modestly higher, on average, in people with major depressive disorder than in matched controls. This part of the picture is well replicated.
Step two, causation. Mendelian-randomisation studies use genetic variants as a natural experiment, since your genes are fixed at conception and cannot be caused by your current mood. They give some support to IL-6 signalling playing a causal role, while the genetic evidence for acting as an independent cause is weaker and more mixed — which fits the generator picture, where the status light cannot itself be what is draining the fuel.
Step three, treatment. Trials of anti-inflammatory drugs show a genuinely mixed picture. For example, a well-known trial of infliximab (a drug that blocks the cytokine TNF-alpha) found no overall benefit across all participants; a secondary, inflammation-stratified analysis then found a benefit signal in those who started with high inflammation. An exploratory finding inside a negative trial is a much weaker thing than a positive trial, and treating the two as equivalent is the single most common error on this topic.
Check your own answer against this table before you settle on which mechanism a stem is describing.
| Looks like inflammatory depression | How to tell it apart |
|---|---|
| A raised from infection, autoimmune disease or recent injury | CRP is non-specific; exclude these more common causes before invoking a psychiatric mechanism |
| IL-10 (an anti-inflammatory cytokine) | Moves in the OPPOSITE direction — some studies find it relatively reduced in depression, unlike the raised IL-6/CRP pattern |
| The monoamine-deficiency model of depression | A different explanatory level (synaptic availability, not immune signalling); the two sit alongside each other, not in competition |
| A patient with classic low mood, guilt and no marker data | Nothing here requires the inflammatory hypothesis to be invoked at all — it applies specifically to the subgroup with confirmed raised markers |
IL-6 and are not diagnostic tests for depression and are not part of the routine diagnostic work-up for a depressive episode, which still rests on clinical history and mental state examination against standard diagnostic criteria. Where a marker IS raised in a depressed patient, the correct first move is the same as in any other patient: look for infection, autoimmune disease, recent injury or another inflammatory cause before assuming it reflects the depressive illness itself.
No UK guideline — including NICE's depression guidance (NG222) — recommends measuring or IL-6 to select or monitor treatment, and no anti-inflammatory drug is licensed or guideline-endorsed as a depression treatment. What actually happens in current NHS practice is standard NG222-guided care: psychological therapy and/or an antidepressant, chosen and monitored the usual way, regardless of inflammatory marker status. The trial evidence for targeting inflammation directly remains research-stage, promising in a defined subgroup but not yet strong or consistent enough to change a guideline. Switching the generator off only helps the factories where the generator was genuinely the problem, and most depressed patients' production line was never running on generator power at all.
The exam's favourite trap here is collapsing three separate claims — association, causation, treatment implication — into one. Whenever a stem gives you a finding about IL-6 or , ask yourself which of the three it is actually testing before you commit to an answer. Put this to yourself plainly: why is finding "depressed patients have higher CRP on average" much weaker evidence than finding "a genetic variant that changes IL-6 signalling changes depression risk" — even though both point in the same direction?
IL-6 and run modestly higher in roughly a third of people with major depressive disorder, IL-6 signalling carries some genuine (though not CRP-level) causal genetic support, anti-inflammatory trial evidence is honestly mixed, and no guideline yet recommends acting on either marker to treat depression.